KEGG   DRUG: Elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil
Entry
D10756            Mixture   Drug                                   
Name
Elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil;
Stribild (TN)
Product
STRIBILD (Gilead Sciences)
Component
Elvitegravir [DR:D06677], Cobicistat [DR:D09881], Emtricitabine [DR:D01199], Tenofovir disoproxil fumarate [DR:D01982]
Class
Antiviral
 DG03107  Anti-HIV agent
Metabolizing enzyme substrate
 DG01644  CYP2D6 substrate
 DG01633  CYP3A/CYP3A4 substrate
Metabolizing enzyme inhibitor
 DG01645  CYP2D6 inhibitor
 DG02852  CYP3A/CYP3A4 inhibitor
Transporter inhibitor
 DG01622  ABCB1 inhibitor
Remark
ATC code: J05AR09
Product: D10756<US>
Efficacy
Antiviral
  Disease
HIV-1 infection [DS:H01563]
Comment
Elvitegravir is metabolized by CYP3A.
Cobicistat is metabolized by CYP3A with some contribution from by CYP2D6 and it is an inhibitor of CYP3A, CYP2D6 and P-glycoprotein (P-gp).
Target
HIV-1 reverse transcriptase [KO:K24802]
HIV-1 integrase [KO:K24803]
  Pathway
ko03230  Viral genome structure
ko03240  Viral replication
ko03250  Viral life cycle - HIV-1
Metabolism
Enzyme: CYP3A [HSA:1576 1577 1551]; CYP2D6 [HSA:1565]
Interaction
CYP inhibition: CYP3A [HSA:1576 1577 1551], CYP2D6 [HSA:1565]
Transporter inhibition: ABCB1 [HSA:5243]
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J05 ANTIVIRALS FOR SYSTEMIC USE
   J05A DIRECT ACTING ANTIVIRALS
    J05AR Antivirals for treatment of HIV infections, combinations
     J05AR09 Emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat
      D10756  Elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil <US>
USP drug classification [BR:br08302]
 Antivirals
  Anti-HIV Combinations
   Cobicistat/ Elvitegravir/ Emtricitabine/ Tenofovir Disoproxil Fumarate
    D10756  Elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil
Drug groups [BR:br08330]
 Antiviral
  DG03107  Anti-HIV agent
   D10756  Elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil
 Metabolizing enzyme substrate
  DG01644  CYP2D6 substrate
   D10756  Elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil
  DG01633  CYP3A/CYP3A4 substrate
   D10756  Elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil
 Metabolizing enzyme inhibitor
  DG01645  CYP2D6 inhibitor
   D10756  Elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil
  DG02852  CYP3A/CYP3A4 inhibitor
   D10756  Elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil
 Transporter inhibitor
  DG01622  ABCB1 inhibitor
   D10756  Elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil
Drug classes [BR:br08332]
 Antiviral
  DG03107  Anti-HIV agent
   D10756  Elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil
Antimicrobials [BR:br08307]
 Antivirals
  Genome replication inhibitor
   HIV integrase inhibitor
    D10756  Elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D10756
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10756
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D10756
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10756
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D10756
 Drug transporters
  D10756
Other DBs
PubChem: 273220352
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system